Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial
Louis Chaykin, Anuj Bhargava, Raymond de la Rosa, Carol H Wysham, Lone Nørgård Troelsen, Signe H Østoft, Athena Philis-Tsimikas, Louis Chaykin, Anuj Bhargava, Raymond de la Rosa, Carol H Wysham, Lone Nørgård Troelsen, Signe H Østoft, Athena Philis-Tsimikas
Abstract
IN BRIEF Hispanic patients with type 2 diabetes have poorer glycemic control and are at higher risk of severe diabetes complications and mortality than non-Hispanic white patients. This post hoc analysis investigated the safety and efficacy of insulin degludec versus insulin glargine 100 units/mL (glargine U100) in the Hispanic patient subpopulation from the SWITCH 2 trial. In Hispanic patients, hypoglycemia was consistently lower and nocturnal hypoglycemia was significantly lower with degludec versus glargine U100 at similar levels of glycemic control. Overall, results in Hispanic patients in SWITCH 2 were consistent with those in non-Hispanic patients.
Figures
References
- American Diabetes Association Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033–1046
- Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA 2015;314:1021–1029
- Centers for Disease Control and Prevention Table 40. Diabetes prevalence and glycemic control among adults aged 20 and over, by sex, age, and race and Hispanic origin: United States, selected years 1988–1994 through 2011–2014 [article online], 2015. Available from . Accessed 21 October 2017
- Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA 2003;290:1884–1890
- Ferrannini E, Gastaldelli A, Matsuda M, et al. . Influence of ethnicity and familial diabetes on glucose tolerance and insulin action: a physiological analysis. J Clin Endocrinol Metab 2003;88:3251–3257
- Haffner SM, D’Agostino R, Saad MF, et al. . Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic whites. The Insulin Resistance Atherosclerosis Study. Diabetes 1996;45:742–748
- Ford ES, Maynard LM, Li C. Trends in mean waist circumference and abdominal obesity among US adults, 1999–2012. JAMA 2014;312:1151–1153
- Caballero AE. Understanding the Hispanic/Latino patient. Am J Med 2011;124:S10–S15
- United States Census Bureau Quick facts: United States [article online]. Available from . Accessed 8 May 2017
- Colby SL, Ortman JM. Projections of the size and composition of the U.S. population: 2014 to 2060. In: Current Population Reports. Washington, DC, U.S. Census Bureau, 2015
- Handelsman Y, Bloomgarden ZT, Grunberger G, et al. . American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for developing a diabetes mellitus comprehensive care plan—2015. Endocr Pract 2015;21(Suppl. 1):S1–S87
- American Diabetes Association Introduction. In Standards of Medical Care in Diabetes—2017. Diabetes Care 2017;40(Suppl. 1):S1–S2
- Schneiderman N, Llabre M, Cowie CC, et al. . Prevalence of diabetes among Hispanics/Latinos from diverse backgrounds: the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Diabetes Care 2014;37:2233–2239
- McWilliams JM, Meara E, Zaslavsky AM, Ayanian JZ. Differences in control of cardiovascular disease and diabetes by race, ethnicity, and education: U.S. trends from 1999 to 2006 and effects of medicare coverage. Ann Intern Med 2009;150:505–515
- Zhang X, Saaddine JB, Chou CF, et al. . Prevalence of diabetic retinopathy in the United States, 2005–2008. JAMA 2010;304:649–656
- Sinha SK, Shaheen M, Rajavashisth TB, Pan D, Norris KC, Nicholas SB. Association of race/ethnicity, inflammation, and albuminuria in patients with diabetes and early chronic kidney disease. Diabetes Care 2014;37:1060–1068
- Lavery LA, Armstrong DG, Wunderlich RP, Tredwell J, Boulton AJ. Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. Diabetes Care 2003;26:1435–1438
- Dominguez K, Penman-Aguilar A, Chang MH, et al. . Vital signs: leading causes of death, prevalence of diseases and risk factors, and use of health services among Hispanics in the United States: 2009–2013. Morb Mortal Wkly Rep 2015;64:469–478
- Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005;28:2543–2545
- Campos C. Addressing cultural barriers to the successful use of insulin in Hispanics with type 2 diabetes. South Med J 2007;100:812–820
- Shi L, Shao H, Zhao Y, Thomas NA. Is hypoglycemia fear independently associated with health-related quality of life? Health Qual Life Outcomes 2014;12:167.
- Gutiérrez R, Ferro A, Caballero A. Myths and misconceptions about insulin therapy among Latinos/Hispanics with diabetes: a fresh look at an old problem. J Diabetes Metab 2015;6
- Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012;14:944–950
- Wysham C, Bhargava A, Chaykin L, et al. . Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: The SWITCH 2 randomized clinical trial. JAMA 2017;318:45–56
- Ratner R, Gough SC, Mathieu C, et al. . Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2013;15:175–184
- Seaquist ER, Anderson J, Childs B, et al. . Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013;36:1384–1395
- Marso SP, McGuire DK, Zinman B, et al. . Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 2017;377:723–732
- Onishi Y, Ono Y, Rabøl R, Endahl L, Nakamura S. Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. Diabetes Obes Metab 2013;15:826–832
- Warren ML, Chaykin LB, Jabbour S, et al. . Insulin degludec 200 units/mL is associated with lower injection frequency and improved patient-reported outcomes compared with insulin glargine 100 units/mL in patients with type 2 diabetes requiring high-dose insulin. Clin Diabetes 2017;35:90–95
- Cowie CC, Rust KF, Ford ES, et al. . Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009;32:287–294
- Fernandez A, Quan J, Moffet H, Parker MM, Schillinger D, Karter AJ. Adherence to newly prescribed diabetes medications among insured Latino and white patients with diabetes. JAMA Intern Med 2017;177:371–379
- Ginde AA, Espinola JA, Camargo CA Jr. Trends and disparities in U.S. emergency department visits for hypoglycemia, 1993-2005. Diabetes Care 2008;31:511–513
- Barendse S, Singh H, Frier BM, Speight J. The impact of hypoglycaemia on quality of life and related patient-reported outcomes in type 2 diabetes: a narrative review. Diabet Med 2012;29:293–302
- Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011;14:665–671
- Bron M, Marynchenko M, Yang H, Yu AP, Wu EQ. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Postgrad Med 2012;124:124–132
Source: PubMed